HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Reversible Cancer Therapeutics-related Cardiac Dysfunction Complicating Intra-cardiac Thrombi

This item is licensed under: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:https://doi.org/10.2169/internalmedicine.4792-20


Title: Reversible Cancer Therapeutics-related Cardiac Dysfunction Complicating Intra-cardiac Thrombi
Authors: Tsujinaga, Shingo Browse this author →KAKEN DB
Iwano, Hiroyuki Browse this author →KAKEN DB
Oshino, Tomohiro Browse this author
Kadosaka, Takahide Browse this author
Mizuguchi, Yoshifumi Browse this author
Motoi, Ko Browse this author
Chiba, Yasuyuki Browse this author
Koya, Taro Browse this author
Temma, Taro Browse this author
Kamiya, Kiwamu Browse this author →KAKEN DB
Fukushima, Arata Browse this author →KAKEN DB
Koizumi, Takuya Browse this author
Sato, Tomoya Browse this author
Takenaka, Sakae Browse this author
Tada, Atsushi Browse this author
Ishizaka, Suguru Browse this author
Sarashina, Miwa Browse this author
Omote, Kazunori Browse this author →KAKEN DB
Kamada, Rui Browse this author →KAKEN DB
Konishi, Takao Browse this author
Sato, Takuma Browse this author
Nagai, Toshiyuki Browse this author →KAKEN DB
Yamashita, Hiroko Browse this author →KAKEN DB
Anzai, Toshihisa Browse this author →KAKEN DB
Keywords: epirubicin
bevacizumab
cardiotoxicity
heart failure
thrombus
Issue Date: 2020
Publisher: 日本内科学会(The Japanese Society of Internal Medicine)
Journal Title: Internal medicine
Volume: 59
Issue: 17
Start Page: 2155
End Page: 2160
Publisher DOI: 10.2169/internalmedicine.4792-20
Abstract: Epirubicin-based chemotherapy carries a risk of inducing heart failure, although the frequency is rare. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has recently been widely used in patients with recurrent breast cancer as a first-line chemotherapeutic agent. Heart failure or arterial thromboembolism has been reported as a rare cardiovascular complication of bevacizumab. We herein report a breast cancer patient with reversible cancer therapeutics-related cardiac dysfunction associated with bevacizumab and epirubicin complicating intracardiac thrombi in the left atrium and left ventricle. This case underscores the importance of tailored medical planning according to the individual status in patients receiving anti-cancer therapies.
Rights: http://creativecommons.org/licenses/by-nc-nd/4.0/
Type: article
URI: http://hdl.handle.net/2115/79587
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University